Gyre Therapeutics (NASDAQ:GYRE) Shares Gap Up – Time to Buy?

Gyre Therapeutics, Inc. (NASDAQ:GYRE) gapped up prior to trading on Monday. The stock had previously closed at $4.55, but opened at $4.78. Gyre Therapeutics shares last traded at $5.0050, with a volume of 74,317 shares traded.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on GYRE shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Gyre Therapeutics in a report on Friday, August 7th. Wall Street Zen lowered shares of Gyre Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, October 17th. Finally, Zacks Research raised shares of Gyre Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, October 6th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Gyre Therapeutics currently has a consensus rating of “Reduce”.

Gyre Therapeutics Stock Performance

The stock has a 50 day moving average price of $6.73 and a 200 day moving average price of $6.99. The company has a market cap of $524.65 million, a P/E ratio of -22.40 and a beta of 1.89.

Gyre Therapeutics (NASDAQ:GYRE) last released its earnings results on Friday, August 7th. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.06). Gyre Therapeutics had a negative return on equity of 6.57% and a negative net margin of 15.47%. The business had revenue of $29.11 million during the quarter, compared to the consensus estimate of $26.49 million. As a group, equities research analysts predict that Gyre Therapeutics, Inc. will post -0.61 earnings per share for the current year.

Institutional Trading of Gyre Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the business. Bank of America Corp DE bought a new stake in Gyre Therapeutics in the second quarter worth $83,000. Deutsche Bank AG bought a new stake in Gyre Therapeutics during the second quarter worth approximately $118,000. Dimensional Fund Advisors LP boosted its position in Gyre Therapeutics by 131.8% during the first quarter. Dimensional Fund Advisors LP now owns 25,268 shares of the company’s stock worth $176,000 after purchasing an additional 14,365 shares during the period. Bank of New York Mellon Corp boosted its position in Gyre Therapeutics by 4.7% during the first quarter. Bank of New York Mellon Corp now owns 43,144 shares of the company’s stock worth $301,000 after purchasing an additional 1,941 shares during the period. Finally, SBI Securities Co. Ltd. grew its holdings in Gyre Therapeutics by 1.8% during the third quarter. SBI Securities Co. Ltd. now owns 169,717 shares of the company’s stock valued at $1,244,000 after purchasing an additional 2,967 shares during the last quarter. Institutional investors and hedge funds own 23.99% of the company’s stock.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc is a biopharmaceutical company focused on developing therapies for fibrotic diseases, including pulmonary and liver fibrosis. The company’s lead development program is F351, also known as hydronidone, an investigational small-molecule therapy designed to inhibit the progression of fibrosis.

F351 is being evaluated in clinical programs for idiopathic pulmonary fibrosis and liver fibrosis associated with chronic liver disease, including nonalcoholic steatohepatitis-related fibrosis.